Back
to sessions
Sep 28
Scientific
MODERATOR(S)
Keith Cengel, MD, PhD - University of Pennsylvania
Percy Lee, MD, FASTRO - City of Hope National Medical Center
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
08:00am - 08:10am ET
Is Clinical Target Volume Necessary in Limited-Stage Small Cell Lung Cancer? A Large-Scale Comparative Study
Speaker: Xiaolong Wang, - Cancer Center, Shandong University, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong, Jin, jinan -
08:10am - 08:20am ET
Post-Chemoradiotherapy Molecular Residual Disease (MRD) Clearance Determines Long-Term Survival in Limited-Stage Small Cell Lung Cancer: A Prospective Longitudinal Study
Speaker: Yaru Tian, - Shandong Cancer Hospital and Institute, Jinan -
08:20am - 08:30am ET
Prognostic Value of Baseline Genomic Profiling and Longitudinal ctDNA-Based MRD Monitoring in Limited-Stage Small-Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Speaker: Siyuan Huo, - Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer and Tianjin Key Laboratory of Cancer Prevention and Therapy, Ti, Tianjin -
08:30am - 08:40am ET
Postoperative Hypofractionated Radiotherapy for Thymic Epithelial Tumors: Efficacy and Safety Results from a Prospective, Single-Center, Phase II Trial
Speaker: Zhihui Zhang, MD, PhD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy, Beijing -
08:40am - 08:50am ET
Combining SBRT with GM-CSF and Peg-IFNa to Induce Abscopal Effects In Previously Treated Patients with Metastatic Thymic Tumors: A Single Institution, Phase II Trial
Speaker: Min Fan, MD, PhD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai